1. Scrip
  2. >>Business

Three-Plant FDA Warning Spooks Dr Reddy's, Clouds ANDAs

 
• By Anju Ghangurde

Dr Reddy's Laboratories was bludgeoned on Indian bourses after the firm said that it had received FDA warning letters at three manufacturing sites, including an oncology plant, in India.

Dr Reddy's Laboratories was bludgeoned on Indian bourses after the firm said that it had received FDA warning letters at three manufacturing sites, including an oncology plant, in India.

The announcement, coming days ahead of India's Diwali festival, ruffled investors, who believe that the development could potentially put at...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 
• By Andrew McConaghie

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.